한글목차

세계의 항진균제 시장은 2030년까지 220억 달러에 달할 전망

2023년에 165억 달러로 추정되는 세계의 항진균제 시장은 분석 기간인 2023-2030년에 CAGR 4.2%로 성장하며, 2030년에는 220억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 아졸 약제 클래스는 CAGR 4.5%를 기록하며, 분석 기간 종료시에는 107억 달러에 달할 것으로 예측됩니다. 에키노칸딘류 약제 클래스 부문의 성장률은 분석 기간 중 CAGR 3.9%로 추정됩니다.

미국 시장은 44억 달러로 추정, 중국은 CAGR 6.6%로 성장 예측

미국의 항진균제 시장은 2023년에 44억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 47억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년 CAGR은 6.6%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.7%와 3.4%로 예측됩니다. 유럽에서는 독일이 CAGR 3.2%로 성장할 것으로 예측됩니다.

세계의 항진균제 시장 - 주요 동향과 촉진요인 정리

현대 의료에서 항진균제가 중요한 이유는?

항진균제는 표면적인 피부 증상에서 심각한 전신 감염에 이르기까지 진균 감염증에 대항하는 역할을 하므로 현대 의학에서 필수적인 역할을 합니다. 이러한 감염은 효모, 곰팡이, 피부사상균과 같은 진균에 의해 발생하며 피부, 손톱, 폐, 혈류 등 신체의 여러 부위에 영향을 미칠 수 있습니다. 무좀이나 백선균과 같은 표재성 감염은 흔하며 외용 항진균 크림으로 쉽게 치료할 수 있습니다. 그러나 칸디다균이나 아스페르길루스균 등에 의한 전신 감염은 특히 면역력이 약한 환자에게는 생명을 위협할 수 있습니다. 이러한 환자에는 화학요법을 받고 있는 환자, 장기 이식 환자, HIV/AIDS 환자 등이 포함됩니다. 따라서 항진균제는 일반적인 진균 감염을 치료하고 취약한 사람들의 심각한 합병증을 예방하는 데 필수적입니다.

항진균제의 주요 유형과 그 메커니즘은 무엇인가?

항진균제의 주요 계열에는 아졸계, 폴리엔계, 에키노칸딘계, 알릴아민계가 있으며, 각각 작용기전이 다릅니다. 플루코나졸, 이트라코나졸과 같은 아졸계는 곰팡이 세포막의 필수 성분인 에르고스테롤의 합성을 억제합니다. 암포테리신 B나 나이스타틴과 같은 폴리엔계 약제는 에르고스테롤에 결합하여 곰팡이 세포막에 구멍을 뚫어 세포 사멸을 유발합니다. 카스포펀진과 같은 에키노칸딘계 약물은 곰팡이 세포벽의 중요한 구성 성분인 β-글루칸의 합성을 억제하여 세포벽의 완전성을 파괴하여 세포 용해를 유발합니다. 테르비나핀과 같은 알릴아민은 에르고스테롤 합성에 관여하는 또 다른 효소인 스쿠알렌 에폭시다아제를 억제하여 스쿠알렌의 독성 축적과 세포 사멸을 유발합니다. 이러한 다양한 메커니즘을 통해 진균 감염증의 유형과 중증도에 따라 표적 치료가 가능하여 환자의 결과를 개선할 수 있습니다.

기술의 발전은 항진균제 개발에 어떤 영향을 미쳤는가?

기술의 발전은 항진균제 개발에 큰 영향을 미쳐 약효를 개선하고 부작용을 줄이는 데 큰 영향을 미치고 있습니다. 리포좀 제제 및 나노입자 캐리어와 같은 약물전달 시스템의 혁신은 항진균제의 생체 이용률과 표적 전달을 향상시켜 독성을 최소화하고 환자의 순응도를 향상시킵니다. 유전체학 및 분자생물학의 발전은 새로운 약물 표적의 발굴과 독특한 작용기전을 가진 새로운 항진균제의 개발을 촉진하고 있습니다. 고처리량 스크리닝과 계산 약물 설계는 강력한 항진균제 화합물의 발견과 최적화를 가속화하고 있습니다. 또한 여러 항진균제를 병용하는 병용요법 개발은 내성균을 극복하고 치료 결과를 개선하는 데 효과적임이 입증되고 있습니다. 이러한 기술 발전은 항진균제 내성 문제를 해결하고 진균 감염증에 대한 효과적인 치료 옵션을 확대하는 데 매우 중요합니다.

항진균제 시장의 성장을 가속하는 요인은 무엇인가?

항진균제 시장의 성장은 기술 발전, 진균 감염증 유병률 증가, 의료 수요의 진화와 관련된 몇 가지 요인에 의해 주도되고 있습니다. 진균 감염증, 특히 면역 결핍 환자 및 노인의 진균 감염증 유병률 증가가 주요 촉진요인입니다. 항진균제 제형과 전달 시스템의 발전은 치료 효과와 환자 순응도를 높여 시장 성장에 기여하고 있습니다. 또한 광범위 항진균제의 사용 확대와 내성 균주를 표적으로 하는 새로운 약물의 개발도 시장을 촉진하고 있습니다. 또한 진균 감염에 대한 인식이 높아지고 진단 기술이 향상됨에 따라 보다 빠르고 정확한 진단이 가능해짐에 따라 효과적인 치료에 대한 수요가 증가하고 있습니다. 항진균제가 만성질환에 대한 종합적인 치료 계획에 포함되고 고위험군 환자에서 예방적 항진균제 사용 증가 추세는 시장 확대를 더욱 촉진하고 있습니다. 이러한 요인들이 복합적으로 작용하여 항진균제 시장은 견고하고 역동적인 양상을 보이고 있습니다.

조사 대상 기업의 예(주목 11사)

• Abbott Laboratories, Inc.
• Bayer AG
• Enzon Pharmaceuticals, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi SA
• SCYNEXIS, Inc.

목차

제1장 조사 방법

제2장 개요

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장의 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Antifungal Drugs Market to Reach US$22.0 Billion by 2030

The global market for Antifungal Drugs estimated at US$16.5 Billion in the year 2023, is expected to reach US$22.0 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Azoles Drug Class, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$10.7 Billion by the end of the analysis period. Growth in the Echinocandins Drug Class segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 6.6% CAGR

The Antifungal Drugs market in the U.S. is estimated at US$4.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.7 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Antifungal Drugs Market - Key Trends and Drivers Summarized

Why Are Antifungal Drugs Crucial in Modern Medicine?

Antifungal drugs are essential in modern medicine due to their role in combating fungal infections, which can range from superficial skin conditions to severe systemic infections. These infections are caused by fungi such as yeasts, molds, and dermatophytes, which can affect various parts of the body including the skin, nails, lungs, and bloodstream. Superficial infections like athlete’s foot and ringworm are common and easily treatable with topical antifungal creams. However, systemic infections, such as those caused by Candida or Aspergillus species, can be life-threatening, especially in immunocompromised individuals. These patients include those undergoing chemotherapy, organ transplant recipients, and individuals with HIV/AIDS. Therefore, antifungal drugs are vital in both treating common fungal infections and preventing severe complications in vulnerable populations.

What Are the Major Classes of Antifungal Drugs and Their Mechanisms?

The major classes of antifungal drugs include azoles, polyenes, echinocandins, and allylamines, each with distinct mechanisms of action. Azoles, such as fluconazole and itraconazole, inhibit the synthesis of ergosterol, an essential component of fungal cell membranes. Polyenes, including amphotericin B and nystatin, bind to ergosterol, creating pores in the fungal cell membrane, leading to cell death. Echinocandins, such as caspofungin, inhibit the synthesis of β-glucan, a critical component of the fungal cell wall, thereby disrupting cell wall integrity and causing cell lysis. Allylamines, like terbinafine, inhibit squalene epoxidase, another enzyme involved in ergosterol synthesis, resulting in toxic accumulation of squalene and cell death. These different mechanisms allow for targeted treatment based on the type and severity of the fungal infection, improving patient outcomes.

How Are Technological Advancements Influencing Antifungal Drug Development?

Technological advancements are significantly influencing the development of antifungal drugs, leading to improved efficacy and reduced side effects. Innovations in drug delivery systems, such as liposomal formulations and nanoparticle carriers, enhance the bioavailability and targeted delivery of antifungal agents, minimizing toxicity and improving patient compliance. Advances in genomics and molecular biology are facilitating the identification of new drug targets and the development of novel antifungal agents with unique mechanisms of action. High-throughput screening and computational drug design are accelerating the discovery and optimization of potent antifungal compounds. Furthermore, the development of combination therapies, where multiple antifungal agents are used together, is proving effective in overcoming resistance and improving treatment outcomes. These technological advancements are crucial in addressing the challenges of antifungal resistance and expanding the arsenal of effective treatments against fungal infections.

What Factors Are Driving Growth in the Antifungal Drugs Market?

The growth in the antifungal drugs market is driven by several factors related to technological advancements, increasing prevalence of fungal infections, and evolving healthcare needs. The rising incidence of fungal infections, particularly among immunocompromised individuals and the elderly, is a major driver. Advances in antifungal drug formulations and delivery systems are enhancing treatment efficacy and patient adherence, contributing to market growth. The expanding use of broad-spectrum antifungal agents and the development of novel drugs targeting resistant strains are also propelling the market. Additionally, increasing awareness of fungal infections and improved diagnostic techniques are leading to earlier and more accurate diagnosis, driving demand for effective treatments. The integration of antifungal drugs in comprehensive care plans for chronic diseases and the rising trend of prophylactic antifungal use in high-risk populations are further supporting market expansion. These factors collectively contribute to a robust and dynamic market landscape for antifungal drugs.

Select Competitors (Total 11 Featured) -

• Abbott Laboratories, Inc.
• Bayer AG
• Enzon Pharmaceuticals, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi SA
• SCYNEXIS, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Antifungal Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Fungal Infections Throws the Spotlight on Antifungal Drugs
  • Development of Novel Antifungal Agents Expands Addressable Market Opportunity
  • Increasing Prevalence of Immunocompromised Patients Strengthens Business Case for Antifungal Drugs
  • Innovations in Genomics and Molecular Biology Generate New Market Opportunities
  • Advancements in High-Throughput Screening Drives Demand for New Antifungal Compounds
  • Trends in Prophylactic Use of Antifungal Drugs in High-Risk Populations Propel Market Growth
  • Trends in Personalized Medicine and Targeted Therapies Drive Adoption of Advanced Antifungal Drugs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Antifungal Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Antifungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Antifungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Antifungal Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Azoles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Echinocandins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Polyenes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Polyenes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Polyenes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Allylamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Allylamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Allylamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Candidiasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Candidiasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Aspergillosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Aspergillosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Aspergillosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Dermatophytosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Dermatophytosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Dermatophytosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• JAPAN
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• CHINA
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: China 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: China 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• EUROPE
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Antifungal Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Antifungal Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Antifungal Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• FRANCE
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 65: France Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: France 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 68: France Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: France 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• GERMANY
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 83: UK Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 86: UK Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Spain 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Russia 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Antifungal Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Antifungal Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Asia-Pacific 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Australia 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• INDIA
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 122: India Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: India 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 125: India Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: India 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: South Korea 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Antifungal Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Antifungal Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Antifungal Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Latin America 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Argentina 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Brazil 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Mexico 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Rest of Latin America 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Antifungal Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Antifungal Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Antifungal Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Middle East 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Iran 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Israel 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Saudi Arabia 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: UAE 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Rest of Middle East 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030
• AFRICA
  • Antifungal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Antifungal Drugs by Drug Class - Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Antifungal Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins, Polyenes, Allylamines and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Antifungal Drugs by Indication - Candidiasis, Aspergillosis, Dermatophytosis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Africa 16-Year Perspective for Antifungal Drugs by Indication - Percentage Breakdown of Value Sales for Candidiasis, Aspergillosis, Dermatophytosis and Other Indications for the Years 2014, 2024 & 2030

IV. COMPETITION